AbbVie, Inc. (ABBV)

87.13
0.46 0.53
NYSE
Prev Close 87.59
Open 88.17
Day Low/High 86.73 / 88.17
52 Wk Low/High 62.55 / 101.28
Volume 8.76M
Exchange NYSE
Shares Outstanding 1764.83B
Market Cap 153.35B
P/E Ratio 74.91
Div & Yield N.A. (N.A)

3 Biotechs That Are Worth Buying

Many of these stocks are off to the races.

3 Reasons Not to Be Gloomy About the Stock Market

With a weak dollar, calm oil and tame rates, we're doing fine.

Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA

Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA

Galapagos (GLPG) is the latest biotech stock to list on the Nasdaq Market with an impressive first day of trading as the stock traded up 20%.

You Can Almost Smell the Euphoria

The market is a very happy place these days, so be careful.

3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen

3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen

AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.

Janet Yellen, Stock Market Commentator?

It's not the Fed chief's place.

Despite Turmoil, Good Buys Still Exist

Despite Turmoil, Good Buys Still Exist

Drug makers, Apple and other tech stocks among reasonable bargains.

Apple and Gilead on the Earnings Clock

Apple and Gilead on the Earnings Clock

What to expect and focus on when these two report this week.

Until Next Time ...

The market was a slow-rolling melt-up today as Nasdaq closed at all-time highs and the S&P 500 closed above all-time levels, but just barely. The Russell 2000 underperformed today. Although the indices did not see much movement, there were some big ...

I'm Going to Keep Riding These Horses

Biogen miss no reason to abandon big 4 of Big Pharma.

Gilead May Be the Cure for the Blues

Gilead May Be the Cure for the Blues

Gilead's Relative Strength Index slope is very strong.

Gilead May Be the Cure for the Blues

Gilead May Be the Cure for the Blues

Gilead's Relative Strength Index slope is very strong.

Abbvie upgraded at BMO

Earnings Growth Boosts AbbVie

Earnings Growth Boosts AbbVie

Drug franchises are still going strong.

Mylan Deal Is All That Shell Is Not

The ecstasy and the agony of M&A all in one day.

Portfolio Managers Shop for Growth

Combined Heinz-Kraft heads a long second-quarter list.

Biotech, Chips Stand Their Ground

You can't help but feel better about both groups.

Biotechs Need to Rest

If there is no catalyst, I'd join those who sell on a bounce.

Backing Away From Biotechs

This sector could see some real damage.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

These Stocks Get Benefit of the Doubt

Market backtracks on skepticism over biotechs.

Market Rewards Biotech Latecomers

It shouldn't be possible, but it never seems too late to get in.

Jobs Report and Biotech Nerves

I am happy to be standing in for Doug Kass today on the Daily Diary. The market-moving event du jour is likely to be the jobs report, which hits an hour before the open. Hopefully it will show the American economy continues to add jobs at the same r...

That's Just What's Supposed to Happen

Stocks that stabilized yesterday were terrific today.

Value in Good Management

Kroger is a good example of execution.

Recommended Reading, Part Deux

In Jim "El Capitan" Cramer's "Return of the Cult Stocks," he talks about comebacks in Tesla (TSLA), Facebook (FB), Netflix (NFLX), Amazon (AMZN) and others -- even Ali Blah Blah (BABA) and GoPro (GPRO) have had a rally, albeit from depressed levels....

Cramer: Return of the Cult Stocks

The cult of the buyer stays devoted to Tesla, Netflix, Amazon and more.

China Cuts Growth Target

And four other things you need to know now.

Dynavax Technologies: A New 'Best Idea'

Dynavax Technologies: A New 'Best Idea'

This vaccine maker is now closer to several important milestones.

Why I Favor Big-Cap Growth Stocks

Why I Favor Big-Cap Growth Stocks

Because now is not the time to get complacent in this market.